{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:38:13Z","timestamp":1793039893227,"version":"4.5.0"},"reference-count":25,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"unspecified","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2023A1515012462"],"award-info":[{"award-number":["2023A1515012462"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204447"],"award-info":[{"award-number":["82204447"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373903"],"award-info":[{"award-number":["82373903"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,10,26]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Oncolytic virus M1 (OVM), a naturally occurring alphavirus, has demonstrated potent antitumor activity in various solid tumor models by inducing immunogenic cell death and activating CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. However, its in vivo efficacy varies widely, and resistance mechanisms remain poorly understood. Tumor-associated macrophages (TAMs), key immunosuppressive cells within the tumor microenvironment, may limit OVM therapeutic potential.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We investigated the role of TAMs in OVM resistance using multiple syngeneic mouse tumor models (MC38 colorectal cancer, KPC1199 pancreatic cancer, RM1 prostate cancer, and B16F10 melanoma). TAMs were depleted using clodronate liposomes or CSF1R (Colony Stimulating Factor 1 Receptor) antibodies. Flow cytometry, mass cytometry, quantitative reverse transcription-PCR, and transcriptomic sequencing were employed to assess TAMs infiltration, viral load, and immune responses. CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells were selectively depleted to determine their functional relevance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TAMs infiltration was positively correlated with resistance to OVM across tumor models. Depletion of TAMs increased intratumoral viral load and promoted accumulation of GZMB\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. RNA sequencing analysis revealed upregulation of antiviral and T-cell immune pathways in TAMs-depleted tumors. Importantly, the therapeutic benefit of TAMs depletion was abrogated on CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell depletion, confirming their essential role in mediating OVM efficacy. In both OVM non-responsive and responsive tumors, TAMs depletion enhanced OVM-mediated tumor suppression and survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      TAMs, particularly M1-like subsets, play a critical role in mediating resistance to OVM therapy by reducing viral persistence and suppressing CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell responses. Targeting TAMs significantly improves the antitumor efficacy of OVM in solid tumors. These findings support the development of TAMs-targeted combination strategies to optimize oncolytic virotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012858","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:10:23Z","timestamp":1763100623000},"page":"e012858","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["TAMs-mediated resistance to oncolytic virus M1 in solid tumors"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2023-9324","authenticated-orcid":false,"given":"Xuanming","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2847-4184","authenticated-orcid":false,"given":"Jingjie","family":"Li","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Sixth Affiliated Hospital Reproductive Medicine Center, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1594-7180","authenticated-orcid":false,"given":"Jiehong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2345-1915","authenticated-orcid":false,"given":"Chaoxin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9632-4859","authenticated-orcid":false,"given":"Honghui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8566-2021","authenticated-orcid":false,"given":"Caixin","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Guo","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center Department of Neurosurgery and Neuro Oncology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0672-4233","authenticated-orcid":false,"given":"Yu","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery\/Neuro-oncology, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2547-4442","authenticated-orcid":false,"given":"Wenfeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1762-9019","authenticated-orcid":false,"given":"Ke","family":"Sai","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery\/Neuro-oncology, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7152-0965","authenticated-orcid":false,"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8822-2657","authenticated-orcid":false,"given":"Guangmei","family":"Yan","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9143-5733","authenticated-orcid":false,"given":"Wenbo","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-0034","authenticated-orcid":false,"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"2026091123004768000_13.11.e012858.1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J National Cancer Center"},{"key":"2026091123004768000_13.11.e012858.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00719-w"},{"key":"2026091123004768000_13.11.e012858.3","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026091123004768000_13.11.e012858.4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300215"},{"key":"2026091123004768000_13.11.e012858.5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1701002114"},{"key":"2026091123004768000_13.11.e012858.6","doi-asserted-by":"crossref","DOI":"10.1038\/nrd.2016.178","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"15","author":"Kaufman","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"2026091123004768000_13.11.e012858.7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jamcollsurg.2018.12.027","article-title":"Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience","volume":"228","author":"Louie","year":"2019","journal-title":"J Am Coll Surg"},{"key":"2026091123004768000_13.11.e012858.8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2217\/fon-2019-0838","article-title":"Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database","volume":"16","author":"Louie","year":"2020","journal-title":"Future Oncol"},{"key":"2026091123004768000_13.11.e012858.9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/hum.2020.271","article-title":"The Identification and Development of a Novel Oncolytic Virus: Alphavirus M1","volume":"32","author":"Cai","year":"2021","journal-title":"Hum Gene Ther"},{"key":"2026091123004768000_13.11.e012858.10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1408759111"},{"key":"2026091123004768000_13.11.e012858.11","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-00921-3","article-title":"Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors","volume":"7","author":"Song","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026091123004768000_13.11.e012858.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.05.008"},{"key":"2026091123004768000_13.11.e012858.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.169"},{"key":"2026091123004768000_13.11.e012858.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2010.01.009"},{"key":"2026091123004768000_13.11.e012858.15","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.217"},{"key":"2026091123004768000_13.11.e012858.16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3909"},{"key":"2026091123004768000_13.11.e012858.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04709-z","article-title":"Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages","volume":"21","author":"Shen","year":"2023","journal-title":"J Transl Med"},{"key":"2026091123004768000_13.11.e012858.18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1063"},{"key":"2026091123004768000_13.11.e012858.19","doi-asserted-by":"crossref","first-page":"197991","DOI":"10.1016\/j.virusres.2020.197991","article-title":"Oncolytic vesicular stomatitis viruses selectively target M2 macrophages","volume":"284","author":"Polzin","year":"2020","journal-title":"Virus Res"},{"key":"2026091123004768000_13.11.e012858.20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00938","article-title":"Myeloid Cell-Derived Arginase in Cancer Immune Response","volume":"11","author":"Grzywa","year":"2020","journal-title":"Front Immunol"},{"key":"2026091123004768000_13.11.e012858.21","doi-asserted-by":"crossref","unstructured":"Liu Y , Cai J , Liu W , et al . Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade. Cell Death Dis 2020;11. doi:10.1038\/s41419-020-03285-0","DOI":"10.1038\/s41419-020-03285-0"},{"key":"2026091123004768000_13.11.e012858.22","doi-asserted-by":"crossref","first-page":"112002","DOI":"10.1016\/j.celrep.2023.112002","article-title":"Type I interferon\/STAT1 signaling regulates UBE2M-mediated antiviral innate immunity in a negative feedback manner","volume":"42","author":"Kong","year":"2023","journal-title":"Cell Rep"},{"key":"2026091123004768000_13.11.e012858.23","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.943","article-title":"CD47-SIRP\u03b1 blocking-based immunotherapy: Current and prospective therapeutic strategies","volume":"12","author":"Bouwstra","year":"2022","journal-title":"Clin Transl Med"},{"key":"2026091123004768000_13.11.e012858.24","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov245"},{"key":"2026091123004768000_13.11.e012858.25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001006","article-title":"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors","volume":"8","author":"Razak","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:01:11Z","timestamp":1789192871000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,13]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/jitc-2025-012858"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012858","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}